IsoRay, Inc. (NYSEMKT: ISR) has released results touting its Cesium-131 brachytherapy seeds. The results came from a prospective study to evaluate the intraoperative brachytherapy involving Cesium-131. ISR said the trial captured 16 patients and 20 tumors.
The most exciting outcome of the trial was the finding that 95% of tumors treated didn’t regrow at the operative site.
According to IsoRay, Inc. (NYSEMKT:ISR), the study focused on the use of its Cesium-131 seeds in the treatment of recurrent aggressive meningiomas. That was done through a technique that has come to be known as “GammaTile” approach. In GammaTile, the seeds were embedded in collagen tiles and then directly applied to the brain tissue. That happened after the removal of tumor.
ISR said that the GammaTile approach used in the study is currently not commercially available.
The outcome of the IsoRay, Inc. (NYSEMKT:ISR) study
Looking at the results, IsoRay, Inc. (NYSEMKT:ISR) said that 95% of the treated tumors during the study didn’t regrow. Although radiation side effects were noted, they weren’t widespread as only 10% of the treatments showed adverse side effects.
David G. Brachman of Barrow Neurological Institute and University of Arizona College of Medicine-Phoenix, was the one who presented the results of the prospective trial at a prestigious peer forum. Brachman observed that ISR’s seeds were used to treat aggressive meningiomas in patients whose tumors had recurred despite previous radiation and surgery procedures.
Challenge for physicians
Because of the recurrence of the tumors, their presence in the brain and failed prior treatments, doctors faced serious challenge dealing with them. But the GammaTile approach used with IsoRay, Inc. (NYSEMKT:ISR)’s Cesium-131 seeds provided a promising therapy pathway. Brachman noted that the Cesium-131 tiles were able to be implanted faster during surgery. The approach also allowed for starting radiation therapy during the resection instead of having to wait for weeks when external beam radiation is used.
As such, the study noted that the novel approach of GammaTile with IsoRay, Inc. (NYSEMKT:ISR)’s Cesium-131 seeds renders greater advantages in combating tumors.